Roles of gut microbes in metabolic‑associated fatty liver disease

Abstract

 

Metabolic‑associated fatty liver disease (MAFLD) is the most common chronic liver disease. Gut dysbiosis is considered a significant contributing factor in disease development. Increased intestinal permeability can be induced by gut dysbiosis, followed by the entry of lipopolysaccharide into circulation to reach peripheral tissue and result in chronic inflammation. We reviewed how microbial metabolites push host physiology toward MAFLD, including short‑chain fatty acids (SCFAs), bile acids, and tryptophan metabolites. The effects of SCFAs are generally reported as anti‑inflammatory and can improve intestinal barrier function and restore gut microbiota. Gut microbes can influence intestinal barrier function through SCFAs produced by fermentative bacteria, especially butyrate and propionate producers. This is achieved through the activation of free fatty acid sensing receptors. Bile is directly involved in lipid absorption. Gut microbes can alter bile acid composition by bile salt hydrolase‑producing bacteria and bacterial hydroxysteroid dehydrogenase‑producing bacteria. These bile acids can affect host physiology by activating farnesoid X receptor Takeda G protein‑coupled receptor 5. Gut microbes can also induce MAFLD‑associated symptoms by producing tryptophan metabolites kynurenine, serotonin, and indole‑3‑propionate. A summary of bacterial genera involved in SCFAs production, bile acid transformation, and tryptophan metabolism is provided. Many bacteria have demonstrated efficacy in alleviating MAFLD in animal models and are potential therapeutic candidates for MAFLD.

Keywords: Bile acids, Gut microbiota, Metabolic‑associated fatty liver disease, Short‑chain fatty acid, Tryptophan